Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam vs Diazepam for Pediatric Status Epilepticus
NCT00621478Phase 3Completed
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Start
- Feb 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lorazepam in status epilepticus (SE) (2 cohorts), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoint: Cessation of convulsions within 10 minutes and sustained absence for 30 minutes. Started Feb 2008; status: completed.
02
Drugs
lorazepam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT00621478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621478.